Tango Therapeutics shares are trading higher after HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $11 to $16.
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co has maintained a Buy rating on Tango Therapeutics and raised its price target from $11 to $16, leading to a rise in the company's stock.
August 11, 2023 | 3:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tango Therapeutics' stock is trading higher after HC Wainwright & Co maintained a Buy rating and raised its price target from $11 to $16.
The positive rating and increased price target from HC Wainwright & Co indicates a strong vote of confidence in Tango Therapeutics. This is likely to attract investors, leading to a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100